Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. LYSOGENE
  6. Summary
    LYS   FR0013233475

LYSOGENE

(LYS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
09/14/2021 09/15/2021 09/16/2021 09/17/2021 09/20/2021 Date
2.28(c) 2.26(c) 2.275(c) 2.27(c) 2.23 Last
20 846 21 955 38 889 34 701 43 958 Volume
+1.56% -0.88% +0.66% -0.22% -1.76% Change
More quotes
Estimated financial data (e)
Sales 2019 16,5 M 19,3 M 19,3 M
Net income 2019 -4,28 M -5,01 M -5,01 M
Net cash position 2019 24,4 M 28,6 M 28,6 M
P/E ratio 2019 -5,76x
Yield 2019 -
Sales 2020 16,4 M 19,3 M 19,3 M
Net income 2020 -5,09 M -5,96 M -5,96 M
Net cash position 2020 17,0 M 19,9 M 19,9 M
P/E ratio 2020 -8,22x
Yield 2020 -
Capitalization 37,2 M 43,7 M 43,6 M
EV / Sales 2019 0,01x
EV / Sales 2020 1,60x
Nbr of Employees 22
Free-Float 86,4%
More Financials
Company
Lysogene SA is a France-based company principally engaged in the bio diagnostics and testing. The Company is focused on the gene therapy biotechnology. The Company develops treatments targeting severe genetic pathologies with central nervous system involvement and high unmet medical needs. It is specialized in the development of intracerebral gene therapy aimed at treating pathologies affecting the central nervous... 
More about the company
All news about LYSOGENE
08/30GLOBAL MARKETS LIVE : Sanofi, Walt Disney, Roche, Flatexdegiro, KBC Group...
08/30LYSOGENE : Announces First Patient in the United States Dosed with LYS-GM101 Inv..
PU
08/30LYSOGENE : Doses First Patient with Investigational Gene Therapy in US to Treat ..
MT
08/30Lysogene Announces First Patient in the United States Dosed with LYS-GM101 In..
CI
06/25LYSOGENE : Proxy Statments
CO
06/11Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conec..
CI
06/10Global markets live: Tesla, BT Group, GameStop, Alibaba, Boeing...
06/09Lysogene Announces First Patient Dosed with LYS-GM101 Investigational Gene Th..
CI
05/20LYSOGENE : Meeting Notice of the Annual Ordinary and Extraordinary General Meeti..
PU
05/20Lysogene Announces Phase 3 Gene Therapy Platform Company Targeting Central Ne..
CI
04/29LYSOGENE : 1st quarter earnings
CO
04/19LYSOGENE : 2020 annual report of liquidity contract
PU
03/31Lysogene S.A. Reports Earnings Results for the Year Ended 31 December 2020
CI
03/31LYSOGENE : Annual results
CO
02/17LYSOGENE : Reports its Cash Position as of 31 December 2020
BU
More news
News in other languages on LYSOGENE
08/30STOCK MARKET PARIS : Paris manque de dynamisme
08/30Les marchés boursiers pas pleinement convaincus par la Fed
08/30STOCK MARKET PARIS : Paris stagne après la Fed
08/30Lysogene administre une thérapie génique expérimentale à un premier patient a..
08/30LYSOGENE : lancement d'un essai dans la gangliosidose
More news
Chart LYSOGENE
Duration : Period :
LYSOGENE Technical Analysis Chart | LYS | FR0013233475 | MarketScreener
Technical analysis trends LYSOGENE
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 2,27 €
Average target price 11,00 €
Spread / Average Target 385%
EPS Revisions
Managers and Directors
Karen Pignet-Aiach Chairman & Chief Executive Officer
StÚphane Durant des Aulnois Chief Financial Officer
Sophie Olivier Chief Medical Officer
Ralph Laufer Chief Scientific Officer
David S. Schilansky Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
LYSOGENE-14.34%44
EXACT SCIENCES CORPORATION-18.37%18 596
GUARDANT HEALTH, INC.2.46%13 376
INVITAE CORPORATION-24.56%6 855
BGI GENOMICS CO., LTD.-28.47%5 830
ADAPTIVE BIOTECHNOLOGIES CORPORATION-32.78%5 595